Refine
Has Fulltext
- yes (75)
Is part of the Bibliography
- yes (75) (remove)
Year of publication
Document Type
- Journal article (68)
- Preprint (4)
- Conference Proceeding (3)
Language
- English (75)
Keywords
- PET (17)
- prostate cancer (13)
- theranostics (13)
- positron emission tomography (11)
- CXCR4 (10)
- PET/CT (10)
- Positronen-Emissions-Tomografie (10)
- PSMA (9)
- PRRT (8)
- molecular imaging (8)
- multiple myeloma (8)
- neuroendocrine tumor (8)
- radioligand therapy (8)
- RADS (4)
- SPECT (4)
- SSTR (4)
- somatostatin receptor (4)
- 18F-DCFPyL (3)
- DaTscan (3)
- FDG (3)
- NET (3)
- PSMA-RADS (3)
- Prostate Cancer (3)
- adrenocortical carcinoma (3)
- chemokine receptor (3)
- endoradiotherapy (3)
- medicine (3)
- peptide receptor radionuclide therapy (3)
- prostate-specific membrane antigen (3)
- 18F-FDG (2)
- 18F-FDG PET/CT (2)
- 68Ga-DOTATATE (2)
- C-X-C motif chemokine receptor 4 (2)
- Ioflupane (2)
- MAG3 (2)
- Medizin (2)
- PSMA I&T (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Parkinson’s disease (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- SUV (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- [68Ga]PentixaFor (2)
- bone disease (2)
- fibroblast activation protein (2)
- lymphoma (2)
- personalized medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- radionuclide therapy (2)
- reporting and data system (2)
- salvage radiotherapy (2)
- tumor heterogeneity (2)
- vandetanib (2)
- 11C-Methionine PET/CT (1)
- 123I-Ioflupane (1)
- 177Lu (1)
- 18-F-fluorothymidine uptake (1)
- 18F-DCFPL (1)
- 18FDG-PET/CT (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATOC (1)
- 68Ga-Pentixafor PET/CT (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- Arginine (1)
- Atherosclerotic plaque (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CYP11B enzymes (1)
- Cardiovascular risk factors (1)
- Combination (1)
- DLBCL (1)
- DNA repair (1)
- DOTA-EB-TATE (1)
- DOTATOC (1)
- DSB damage (1)
- EBRT (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FDG-PET/CT (1)
- FLT-PET (1)
- GCA (1)
- GPR54 (1)
- Ganglia (1)
- HMDP hydroxymethylene diphosphonate (1)
- Hyperkalaemia (1)
- IBA-1 (1)
- IMAZA (1)
- Imaging pitfalls (1)
- KISS1 receptor (1)
- KISS1-54 (1)
- Lysine (1)
- MI-RADS (1)
- MRI (1)
- Macrophage (1)
- Meningioma (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NVP-BGT226 (1)
- PMR (1)
- PROMISE (1)
- PSA (1)
- PSA response (1)
- PSMA PET/CT (1)
- PSMA-617 (1)
- PSMA-TV (1)
- PSMA‐617 (1)
- Pancreas (1)
- Parkinsonism (1)
- Pentixafor (1)
- Peptide receptor radionuclide therapy (1)
- Pitfall (1)
- Positron emission tomography (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotherapy (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT/CT (1)
- SSTR-PET (1)
- Single-Photon-Emissions-Computertomographie (1)
- Somatostatin receptor (1)
- Somatostatin receptor expression (1)
- TBI (1)
- TSPO (1)
- Tracer (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [18F]Fluorodeoxythymidine (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- [\(^{68}\)]KISS1-54 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{68}\)Ga (1)
- \(^{68}\)Ga-Pentixafor (1)
- adrenal incidentaloma (1)
- ageing (1)
- agreement (1)
- amino acids (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- autologous transplantation (1)
- autoradiography (1)
- biokinetics (1)
- biomarker (1)
- bone-marrow (1)
- cancer (1)
- cancer treatment (1)
- caudate nucleus (1)
- cells (1)
- chemokine receptor-4 (1)
- cholinergic activity (1)
- combination (1)
- comparability (1)
- diffuse (1)
- dopamine transporter (DAT) (1)
- early response (1)
- ejection fraction (1)
- esophagogastric junction (1)
- evans blue (1)
- experience (1)
- flare phenomenon (1)
- focal (1)
- follicular lymphoma (1)
- giant cell arteritis (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- head and neck cancer (1)
- health care (1)
- hematotoxicity (1)
- human tumor cell lines (1)
- hyperkalemia (1)
- imaging (1)
- imaging proliferation (1)
- imaging techniques (1)
- immunohistochemistry (1)
- immunostaining (1)
- in vivo imaging (1)
- in-vivo (1)
- inflammation (1)
- inhibition (1)
- interobserver (1)
- interreader (1)
- intraindividual comparison (1)
- involvement (1)
- irradiation (1)
- isotopes (1)
- kidney function (1)
- kisspeptin (1)
- late response (1)
- left-ventricular function (1)
- levodopa-induced dyskinesia (1)
- macrophages (1)
- macroscopic recurrence (1)
- magnetic resonance imaging (1)
- malignancies (1)
- mammalian target of rapamycin (1)
- management (1)
- matched pair (1)
- medullary thyroid carcinoma (1)
- metabolic tumor volume (MTV) (1)
- metabolic tumour volume (MTV) (1)
- methionine (1)
- methylphenidate (1)
- microenvironment (1)
- microglial cells (1)
- mouse (1)
- nephrotoxicity (1)
- neuroendocrine neoplasia (1)
- neuroinflammation (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- ollimator (1)
- overall survival (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- pattern (1)
- peptide receptor (1)
- phosphatidylinositol-3-kinase (1)
- photons (1)
- pleural mesothelioma (1)
- polymyalgia rheumatica (1)
- positron emission tomography/computed tomography (1)
- post-reconstruction filtering (1)
- prediction (1)
- progression (1)
- quality (1)
- quantification (1)
- radiogenomics (1)
- radioiodine (1)
- recurrence (1)
- relapse (1)
- renal scintigraphy (1)
- repair (1)
- reporting and data systems (1)
- responsivity (1)
- sarcoidosis (1)
- scanner (1)
- selpercatinib (1)
- signal to noise ratio (1)
- signaling pathway (1)
- simultaneous integrated boost (1)
- single photon emission computed tomography (SPECT) (1)
- skeletal (1)
- small animal SPECT (1)
- small-animal imaging (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin (1)
- somatostatin receptor (SSTR) (1)
- somatostatin receptors (1)
- staging (1)
- standardization (1)
- standardized reporting (1)
- standardized reporting system (1)
- stem-cell transplantation (1)
- striatum (1)
- super ultraviolet (1)
- survival (1)
- target (1)
- taxane (1)
- thyroid carcinoma (TC) (1)
- thyroid carcinomas (1)
- total lesion PSMA (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- treatment response (1)
- tumor (1)
- tyrosine kinase inhibitor (1)
- vasculature (1)
- vasculitis (1)
- vestibular schwannoma (1)
- weight drop (1)
- α-Particle (1)
- γ-H2AX (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (72)
- Medizinische Klinik und Poliklinik II (16)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (10)
- Urologische Klinik und Poliklinik (10)
- Medizinische Klinik und Poliklinik I (8)
- Pathologisches Institut (8)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (3)
- Comprehensive Cancer Center Mainfranken (3)
- Klinik und Poliklinik für Strahlentherapie (3)
Sonstige beteiligte Institutionen
Background: Ga-[1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) positron emission tomography (PET) is commonly used for the visualization of somatostatin receptor (SSTR)-positive neuroendocrine tumors. SSTR is also known to be expressed on macrophages, which play a major role in inflammatory processes in the walls of coronary arteries and large vessels. Therefore, imaging SSTR expression has the potential to visualize vulnerable plaques. We assessed 68Ga-DOTATATE accumulation in large vessels in comparison to 18F-2-fluorodeoxyglucose (FDG) uptake, calcified plaques (CPs), and cardiovascular risk factors. Methods: Sixteen consecutive patients with neuroendocrine tumors or thyroid cancer underwent both 68Ga-DOTATATE and 18F-FDG PET/CT for staging or restaging purposes. Detailed clinical data, including common cardiovascular risk factors, were recorded. For a separate assessment, they were divided into a high-risk and a low-risk group. In each patient, we calculated the maximum target-to-background ratio (TBR) of eight arterial segments. The correlation of the TBRmean of both tracers with risk factors including plaque burden was assessed. Results: The mean TBR of 68Ga-DOTATATE in all large arteries correlated significantly with the presence of CPs (r = 0.52; p < 0.05), hypertension (r = 0.60; p < 0.05), age (r = 0.56; p < 0.05), and uptake of 18F-FDG (r = 0.64; p < 0.01). There was one significant correlation between 18F-FDG uptake and hypertension (0.58; p < 0.05). Out of the 37 sites with the highest focal 68Ga-DOTATATE uptake, 16 (43.2%) also had focal 18F-FDG uptake. Of 39 sites with the highest 18F-FDG uptake, only 11 (28.2%) had a colocalized 68Ga-DOTATATE accumulation. Conclusions: In this series of cancer patients, we found a stronger association of increased 68Ga-DOTATATE uptake with known risk factors of cardiovascular disease as compared to 18F-FDG, suggesting a potential role for plaque imaging in large arteries. Strikingly, we found that focal uptake of 68Ga-DOTATATE and 18F-FDG does not colocalize in a significant number of lesions.
BACKGROUND:
We observed a disproportional 18 F-fluorothymidine (F-FLT) uptake in follicular lymphoma (FL) relative to its low cell proliferation. We tested the hypothesis that the 'excess' uptake of 18 F-FLT in FL is related to error-prone DNA repair and investigated whether this also contributes to 18 F-FLT uptake in diffuse large B cell lymphoma (DLBCL).
METHODS:
We performed immunohistochemical stainings to assess the pure DNA replication marker MIB-1 as well as markers of both DNA replication and repair like PCNA, TK-1 and RPA1 on lymph node biopsies of 27 FLs and 35 DLBCLs. In 7 FL and 15 DLBCL patients, 18 F-FLT-PET had been performed.
RESULTS:
18 F-FLT uptake was lower in FL than in DLBCL (median SUVmax 5.7 vs. 8.9, p = 0,004), but the ratio of 18 F-FLT-SUVmax to percentage of MIB-1 positive cells was significantly higher in FL compared with DLBCL (p = 0.001). The median percentage of MIB-1 positive cells was 10% (range, 10% to 20%) in FL and 70% (40% to 80%) in DLBCL. In contrast, the median percentages of PCNA, TK-1 and RPA1 positive cells were 90% (range, 80 to 100), 90% (80 to 100) and 100% (80 to 100) in FL versus 90% (60 to 100), 90% (60 to 100) and 100% (80 to 100) in DLBCL, respectively.
CONCLUSIONS:
This is the first demonstration of a striking discordance between 18 F-FLT uptake in FL and tumour cell proliferation. High expression of DNA replication and repair markers compared with the pure proliferation marker MIB-1 in FL suggests that this discordance might be due to error-prone DNA repair. While DNA repair-related 18 F-FLT uptake considerably contributes to 18 F-FLT uptake in FL, its contribution to 18 F-FLT uptake in highly proliferative DLBCL is small. This apparently high contribution of DNA repair to the 18 F-FLT signal in FL may hamper studies where 18 F-FLT is used to assess response to cytostatic therapy or to distinguish between FL and transformed lymphoma.
The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed.
Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients.
Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.
This study aimed to explore the correlation between imaging patterns and clinical features in patients with smoldering multiple myeloma (SMM) who simultaneously underwent 18F-FDG, 11C-Methionine, and 68Ga-Pentixafor positron emission tomography/computed tomography (PET/CT). We retrieved and analyzed clinical characteristics and PET imaging data of 10 patients with SMM. We found a significant correlation between bone marrow (BM) plasma cell (PC) infiltration and mean standardized uptake values (SUV\(_{mean}\)) of lumbar vertebrae L2-L4 on 11C-Methionine PET/CT scans (r = 0.676, p = 0.031) and 68Ga-Pentixafor PET/CT scans (r = 0.839, p = 0.002). However, there was no significant correlation between BM involvement and SUV\(_{mean}\) of lumbar vertebrae L2-L4 on 18F-FDG PET/CT scans (r = 0.558, p = 0.093). Similarly, mean target-to-background ratios (TBR\(_{mean}\)) of lumbar vertebrae L2-L4 also correlated with bone marrow plasma cell (BMPC) infiltration in 11C-Methionine PET/CT (r = 0.789, p = 0.007) and 68Ga-Pentixafor PET/CT (r = 0.724, p = 0.018) PET/CT. In contrast, we did not observe a significant correlation between BMPC infiltration rate and TBR\(_{mean}\) in 18F-FDG PET/CT (r = 0.355, p = 0.313). Additionally, on 11C-Methionine PET/CT scans, we found a significant correlation between BMPC infiltration and TBR\(_{max}\) of lumbar vertebrae L2-L4 (r = 0.642, p = 0.045). In conclusion, 11C-Methionine and 68Ga-Pentixafor PET/CT demonstrate higher sensitivity than 18F-FDG PET/CT in detecting BM involvement in SMM.
Background
Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment.
Methods
To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT).
Results
SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%).
Conclusion
SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.